US Edition
Coulter Partners Successfully Places Three Senior Executives at Augustine Therapeutics - Hunt Scanlon Media
Summary by Hunt Scanlon Media
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Coulter Partners Successfully Places Three Senior Executives at Augustine Therapeutics - Hunt Scanlon Media
Augustine Therapeutics is a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the Histone DeACetylase 6 (HDAC6) enzyme. Commenting on the appointments, Gerhard Koenig, PhD, CEO of Augustine, said: “Augustine is pioneering a new generation of HDAC6 inhibitors and has recently achieved a significant milestone by initiating its first clinical trial …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium